New Releases from NCBI BookshelfDurvalumab (Imfinzi): Therapeutic area: Resectable non–small cell lung cancer: Reimbursement Review [Internet].Durvalumab (Imfinzi): Therapeutic area: Resectable non–small cell lung cancer: Reimbursement Review [Internet].
Post Content
